(FILE 'HOME' ENTERED AT 13:46:27 ON 14 NOV 2007)

FILE 'REGISTRY' ENTERED AT 13:46:50 ON 14 NOV 2007
L1 STR
L2 58 SEARCH L1 CSS FUL
L3 STR L1
L4 1 SEARCH L3 EXACT
L5 2 SEARCH L3 EXACT FUL

FILE 'STNGUIDE' ENTERED AT 13:58:38 ON 14 NOV 2007

FILE 'REGISTRY' ENTERED AT 14:05:09 ON 14 NOV 2007

=> d tot sub bib abs

L5 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
RN 95463-68-6 REGISTRY
ED Entered STN: 23 Mar 1985
CN 1-Naphthaleneheptanoic acid, 8-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-, (βR,δR,1S,2S,6R,8S,8aR)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthaleneheptanoic acid, 8-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-, [1S-[1α(βS*,δS*),2α,6β,8β,8aα]]-
FS STEREOSEARCH
DR 854811-15-7
MF C24 H38 O7
CI COM
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 145:342292 CA
TI Long-acting preparation of statins
IN Zhu, Zuolin; Ye, Hongping; Sun, Meng
PA Huaibei City Huike Pharmaceutical Co., Ltd., Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 16 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1778296	A	20060531	CN 2005-10085860	20050719
	WO 2007009320	A1	20070125	WO 2005-CN1967	20051121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI CN 2005-10085860 20050719

AB The drug delivery system comprises pressure-sensitive adhesive layer containing high mol. polymer of statins, film of dimethicone, drug-storing layer, and proofed breathable sarking. The pressure-sensitive adhesive layer is high mol. polymer of polyacrylic acids. The drug-storing layer contains lanolin, and statin medicine. The statin medicine is lovastatin, simvastatin, pravastatin, atorvastatin, rosuvastatin, fluvastatin, pitavastatin, huivastatin, and their salt, etc. The preparation process comprises (a) preparing blank paste cloth; (b) preparing drug-storing paste cloth; and (3) slicing to obtain the product.

REFERENCE 2

AN 143:248284 CA
TI Preparation of huvastatin compounds as hypolipemic agents
IN Ye, Hongping
PA Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, No pp. given
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1546481	A	20041117	CN 2003-10120030	20031201
	EP 1693360	A1	20060823	EP 2004-797387	20041129
	R: DE, FR, GB				
	US 2007185193	A1	20070809	US 2007-581017	20070412
PRAI	CN 2003-10120030	20031201			
	WO 2004-CN1370	20041129			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I, II and III [wherein R, R', R'' = Me, Et, Pr; M = metal ion Na+, K+; etc.], which are useful as antihyperlipemic agents, were prepared For example, IV was synthesized via (1) ring-opening of lactone I (R = H) with KOH, (2) deprotonation and C-methylation with MeI in THF, and (3) lactonization. The invented compds. possess suitable hydrophilicity, strong antihyperlipemic activity, good medical effect and lower dosage (no data).

REFERENCE 3

AN 143:59730 CA

3

TI Huvastatin and its preparation and formulation comprising the Huvastatin
IN Ye, Hongping; Sun, Meng
PA Huaibei Huike Pharmaceutical, Co. Ltd., Peop. Rep. China
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005054173	A1	20050616	WO 2004-CN1370	20041129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD				
	EP 1693360	A1	20060823	EP 2004-797387	20041129
	R: DE, FR, GB				
	US 2007185193	A1	20070809	US 2007-581017	20070412
PRAI	CN 2003-10120030		20031201		
	WO 2004-CN1370		20041129		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to statin compds., and it discloses novel small mol. compds., i.e., huvastatin, which are classified into I (R = Me, Et, Pr, i-Pr, and Bu), II (R = Me, Et, Pr, i-Pr, Bu; M = Li, Na, K, or Ca), III (R' R''' = Me, Et, Pr, i-Pr, Bu; M = Li, Na, K, or Ca). The invention also provides manufacture methods and the formulations comprising the huvastatin as active components. The present compds. can be used at a lower dosage with respect to the existing statin compds., and also can help to obtain the desired lipid levels for the patients with hyperlipidemia. Huvastatin of the invention has suitable hydrophilicity, stronger potency to reduce lipid levels, good medical effect and lower dose usage.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 4

AN 102:130451 CA
TI ML-236B derivatives
PA Sankyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 59175450	A	19841004	JP 1983-49491	19830324
	JP 03033698	B	19910520		
PRAI	JP 1983-49491		19830324		

GI



I, R=H
II, R=?-OH
III, R=?-OH



IV, R=?-OH
V, R=?-OH

AB Four stereoisomers of ML-236B, II [95398-74-6], III [95463-68-6], IV [95398-75-7], and V [95463-69-7], are produced by incubating ML-236A (I) [58889-19-3] with microorganisms capable of 3- or 6-hydroxylation of I. Thus, Mucor hiemalis hiemalis was shake-cultured at 25° for 4 days on a medium containing glucose 1, peptone 0.2, meat extract 0.1, yeast extract 0.1, and corn steep liquor 0.3%. I was added to the culture to a final concentration of 0.05%, and the medium was shaken at 26° for addnl. 6 days. The culture contained 70 mg II/L. Similarly, III was produced by incubating I with Syncephalastrum nigricans. II and III showed marked anticholesteremic activity by inhibiting 3-hydroxy-3-methylbutaryl-CoA reductase.

L5 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
RN 95398-74-6 REGISTRY
ED Entered STN: 23 Mar 1985
CN 1-Naphthaleneheptanoic acid, 8-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-, [1S-[1α(βS*,δS*),2α,6α,8β,8aα]]- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C24 H38 O7
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1



I, R=H

II, R=?-OH

III, R=?-OH



IV, R=?-OH

V, R=?-OH

AB Four stereoisomers of ML-236B, II [95398-74-6], III [95463-68-6], IV [95398-75-7], and V [95463-69-7], are produced by incubating ML-236A (I) [58889-19-3] with microorganisms capable of 3- or 6-hydroxylation of I. Thus, Mucor hiemalis hiemalis was shake-cultured at 25° for 4 days on a medium containing glucose 1, peptone 0.2, meat extract 0.1, yeast extract 0.1, and corn steep liquor 0.3%. I was added to the culture to a final concentration of 0.05%, and the medium was shaken at 26° for addnl. 6 days. The culture contained 70 mg II/L. Similarly, III was produced by incubating I with Syncephalastrum nigricans. II and III showed marked anticholesteremic activity by inhibiting 3-hydroxy-3-methylbutaryl-CoA reductase.

```
=> d his

     (FILE 'HOME' ENTERED AT 13:46:27 ON 14 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 13:46:50 ON 14 NOV 2007
L1             STR
L2              58 SEARCH L1 CSS FUL
L3              STR L1
L4               1 SEARCH L3 EXACT
L5               2 SEARCH L3 EXACT FUL

     FILE 'STNGUIDE' ENTERED AT 13:58:38 ON 14 NOV 2007

     FILE 'REGISTRY' ENTERED AT 14:05:09 ON 14 NOV 2007

=> d l3
L3 HAS NO ANSWERS
L3              STR
```



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE

=>